FDA Approves Apadaz (benzhydrocodone and acetaminophen) for the Short-Term Management of Acute Pain - Hallo friendsLET'S HEALTHY LIFE, In the article you read this time with the title FDA Approves Apadaz (benzhydrocodone and acetaminophen) for the Short-Term Management of Acute Pain, We have prepared this article for you to read and retrieve information therein. Hopefully the contents of postings Article cough, Article diabetes, Article diseases, Article in general, Article Phytotherapy, Article skin diseases, We write this you can understand. Alright, good read.

Title : FDA Approves Apadaz (benzhydrocodone and acetaminophen) for the Short-Term Management of Acute Pain
link : FDA Approves Apadaz (benzhydrocodone and acetaminophen) for the Short-Term Management of Acute Pain

FDA Approves Apadaz (benzhydrocodone and acetaminophen) for the Short-Term Management of Acute Pain

In continuation of my update on Apadaz 

KemPharm, Inc.     announced  the   FDA  approval of  its New Drug Application (NDA) for Apadaz for the short-term (no more than 14 days) management of acute pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate. Apadaz is an immediate release (IR) combination of KemPharm’s prodrug, benzhydrocodone, and acetaminophen (APAP).

benzhydrocodone               

“The approval of Apadaz is a significant milestone for KemPharm as it creates the opportunity to introduce what we believe is a differentiated product for the short-term management of acute pain,” said Travis Mickle, Ph.D., KemPharm President and Chief Executive Officer. “Based on its unique properties, we firmly believe there is a commercial pathway for Apadaz in what is a very high-volume market. We are excited by the opportunity Apadaz offers to patients and for physicians who now have the option of prescribing a differentiated product.”

“In addition to today’s approval, the U.S. Drug Enforcement Administration (DEA) has indicated that it is their intent to schedule Apadaz as a C-II product and will provide an allocation of the Active Pharmaceutical Ingredient (API) consistent with those scheduling provisions,” added Dr. Mickle. “This prompt decision by the DEA essentially completes the regulatory process with both Agencies and allows us to shift our focus towards the product launch.”

FDA Approves Apadaz (benzhydrocodone and acetaminophen) for the Short-Term Management of Acute Pain

Medicinal Chemistry

Thus Article FDA Approves Apadaz (benzhydrocodone and acetaminophen) for the Short-Term Management of Acute Pain

That's an article FDA Approves Apadaz (benzhydrocodone and acetaminophen) for the Short-Term Management of Acute Pain This time, hopefully can give benefits to all of you. well, see you in posting other articles.

You are now reading the article FDA Approves Apadaz (benzhydrocodone and acetaminophen) for the Short-Term Management of Acute Pain with the link address https://letslifes.blogspot.com/2018/03/fda-approves-apadaz-benzhydrocodone-and.html

Tweet

Subscribe to receive free email updates: